TPS 105 ALISertib in Combination With Endocrine Therapy in Patients With Hormone Receptor-Positive, HER2-Negative Recurrent or Metastatic Breast Cancer: the Phase 2 ALISCA-Breast1 Study
Background
Despite the wide range of available treatment options for patients with hormone receptor–positive/HER2-negative (HR+/HER2–) recurrent or metastatic breast cancer, optimal treatment after progression on CDK4/6 inhibitors (CDK4/6i) remains unclear. Several mechanisms of resistance to CDK4/6i have been postulated, including increased expression of Aurora kinase A (AURKA), a key regulator of mitosis associated with poor prognosis in multiple tumor types. Further implicated in CDK 4/6i resistance, high c-Myc or RB1 loss of function (LOF) have been associated with transcriptional co-regulation or synthetic lethality,…